The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.

Charles River Laboratories will pay $60 million for the remaining shares of PathoQuest and $510 million for acquiring K.F.

Polygon Labs signaled that it’s becoming a regulated payments company by acquiring Coinme and Sequence for a combined $250 ...

An international team of scientists has analyzed the ongoing colonization by two retroviruses of the germline of koalas and ...

KNOXVILLE, TN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Daisy Genomics Inc. (“Daisy Genomics”) and New Day ...

Combining virtual dental care with licensed dentists and an innovative oral cancer diagnostics solution ensures all ...

Geneticist Dr. Robert Green is sequencing the DNA of healthy newborns to find hidden disease risks. This knowledge can save ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

The companies aim to advance the development of next-generation epigenetic sequencing and liquid biopsy tools for colorectal cancer detection.

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and ...

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.